Analytical Data
-
Gene name
HLA-A*11:01&B2M&EGFR(KITDFGRAK) Monomer
- Application
-
Alternative Names
HLA-A*1101 & B2M & EGFR (KITDFGRAK)
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AAV53343.1 (G25-T305)&P61769
-
Expression Region
AAV53343.1 (G25-T305)&P61769 (I21-M119)&KITDFGRAK
-
Molecular Weight
40-43 kDa and 11 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The HLA-A*11:01&B2M&EGFR(KITDFGRAK) monomer is a recombinant protein complex that plays a crucial role in understanding immune responses, particularly in the context of tumor immunology and vaccine development. HLA-A*11:01 is a specific allele of the human leukocyte antigen (HLA) class I molecule, which is vital for presenting peptide antigens to CD8+ T cells, facilitating immune recognition and response to malignancies. The incorporation of beta-2-microglobulin (B2M) is essential for the proper folding and stability of the HLA-A molecule, ensuring effective antigen presentation. The peptide EGFR (KITDFGRAK) derived from the epidermal growth factor receptor (EGFR) is of significant interest due to its overexpression in many tumors, making it a potential target for immunotherapy. Studying this recombinant protein allows researchers to explore how the immune system can recognize and target tumor cells expressing the EGFR peptide, thereby paving the way for personalized cancer therapies. Understanding the interaction between HLA molecules and their presented peptides contributes to the broader field of immunology, providing insights into the development of vaccines that elicit robust T cell responses against specific tumor antigens.
